Drugs / Pentavalent Meningococcal ABCYW vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06647407 | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06128733 | Oct 2023 → Aug 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentavalent Meningococcal ABCYW vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06647407 ↗ |
| Modality | Vaccine | “Pentavalent Meningococcal ABCYW vaccine” NCT06128733 ↗ |